Canada’s CBC News is reporting on a study showing a way to possibly prevent one type of skin cancer. A Stanford dermatologist found that a commonly used anti-inflammatory can reduce the risk of basal cell carcinoma:
In a small, double-blinded, randomized, three-year clinical trial of 60 people genetically predisposed to basal cell carcinoma, a type of skin cancer, researchers found that those who took 200 milligrams of celecoxib (Celebrex and Onsenal) orally reduced the number of tumours by 50 per cent.
From lead researcher Jean Tang, MD, PhD: “Basal cell carcinomas are the most common human cancer in the United States, and their incidence is increasing steadily. This work identifies a possible way to prevent them.”
Tang’s work appears in the Jan. 5 issue of Cancer Prevention Research. More on the study can be found in this release.